Skip to main content

International Psoriasis Council

Advancing Knowledge. Improving Care.

Skin-Derived Myeloid Precursors and Joint-Resident Fibroblasts Spread Psoriatic Disease from Skin to Joints

Helen Young, MB, ChB, PhD, FRCP

The University of Manchester

Manchester, United Kingdom

IPC Councilor

Bio

PUBLICATION

Skin-Derived Myeloid Precursors and Joint-Resident Fibroblasts Spread Psoriatic Disease from Skin to Joints. Raimondo MG, Mohammadian H, Angeli MR, et al. Nat Immunol. 2026;27(1):35-47. doi:10.1038/s41590-025-02351-z.

Why This Article Was Chosen

The sequential progression of psoriatic disease from the skin to the joints suggests a mechanistic axis between both organs.  Recent studies demonstrating the recirculation of skin-derived tissue-resident memory T cells into the blood in individuals with PsA1, and clonal expansion of tissue-resident T cells poised to produce IL-17 from lesional to nonlesional psoriatic skin2 have encouraged a research focus on the cellular and molecular mechanisms driving the evolution of psoriatic disease and specifically the spread of inflammatory disease from skin to joints.  In this paper, the authors undertake a systematic and unbiased analysis of cell migration in psoriatic disease to determine the mechanisms by which inflammation spreads between the skin and joints, and take a translational focus to identify new therapeutic targets, improve patient outcomes, and advance personalized medicine in the treatment of psoriatic disease.

Commentary

Psoriatic disease is a systemic, immune-mediated condition that affects the skin and/or joints.3  Skin inflammation (psoriasis) typically precedes joint inflammation (psoriatic arthritis (PsA)) in about 80% of individuals,4 with approximately 30% of individuals with psoriasis developing arthritis.5  Indeed, this sequential progression of psoriatic disease, from skin to joints, suggests a mechanistic axis and spatio-temporal link between both organs.

It is well established that psoriatic disease is associated with increased expression of interleukin-23/interleukin-17 (IL-23/IL-17) and tumor necrosis factor (TNF)-a.6,7  In addition, genome-wide association studies have identified genetic variants associated with psoriatic disease, including HLA-C and HLA-B.8  However, the underlying mechanism of progression from psoriasis to PsA remains largely unknown, and currently, there is no reliable molecular mechanism or biomarker that can predict which individuals with psoriasis will develop PsA.9

In this paper, the authors induced psoriasis-like skin disease in photoconvertible mice.  Following this, sequencing and computational characterization of skin-derived cells in the joints identified a population of CD2+MHC-II+CCR2+ myeloid precursors that build a skin-derived myeloid cell compartment in the joints.   Single-cell cross-species reference mapping and mitochondrial variant tracing demonstrated the migration of an orthologous human population of CD2+MHC-II+CCR2+ myeloid precursors between the skin and synovium, evidencing that leukocyte trafficking is conserved between mice and humans.  However, migration of CD2+ MHC-II+ CCR2+ myeloid precursors alone was insufficient to induce arthritis.

Further studies, including interactome analysis of the joints, demonstrated that, in a second step, resident regulatory CD200+ fibroblasts prime CD2+MHC-II+CCR2+ myeloid precursors, which subsequently control IL-17 expression in T cells.  These data establish that the local microenvironment, particularly CD200+ fibroblasts, acts as gatekeepers of arthritis, engaging the checkpoint receptor CD200R1 on migrating CD2+ MHC-II+ CCR2+ myeloid precursors.  Consequently, intervention with an antibody to CD200 polarized CD2+MHC-II+CCR2+ myeloid precursors toward a proinflammatory phenotype in vitro and enabled the in vivo spread of psoriatic disease from the skin to the joints, even in initially arthritis-resistant mice.

Taken together, these data confirm that the spread of inflammation (from skin to joints) requires a distinct migratory myeloid precursor population and a permissive local tissue environment, analogous to tumor metastasis.

In summary, this paper sheds light on a previously unexplored aspect of psoriatic disease pathogenesis.  Taking a translational perspective and by extrapolating their observations to humans, the authors confirmed conservation of leukocytes from the skin and synovia across species.  By utilizing the MAESTER method10 to track mitochondrial variants based on mRNA, the authors successfully corroborated the presence of a skin–joint axis in humans.  In elegant studies, the authors demonstrated increased abundance of precursors in individuals with psoriasis/PsA compared with healthy controls, suggesting that their migration occurs independently of joint involvement but also constitutes a prerequisite for the spread of inflammation from the skin to the joints. The consistency of their results across species highlights the conserved nature of this pathomechanism and offers new perspectives for developing novel diagnostic and therapeutic strategies.  Indeed, this work specifically highlights the CD200–CD200R1 axis as a promising target for preventive medicine, and, notably, the research team recently identified a CD200+ fibroblast subtype that contributes to the resolution of inflammation in arthritis.11

Nevertheless, although many cases of PsA are preceded by cutaneous psoriasis, a notable proportion of individuals develop PsA without a history of skin symptoms.  Furthermore, genetic studies reveal both shared and distinct genetic factors between skin-limited psoriasis and PsA, suggesting partially divergent pathogenic pathways.12  Although this study focused on the predominant skin-to-joint axis, there remains a need for future research to explore alternative mechanisms.

References

  1. Tissue-Resident Memory CD8+ T Cells from Skin Differentiate Psoriatic Arthritis from Psoriasis. Leijten EF, van Kempen TS, Olde Nordkamp MA, et al. Arthritis Rheumatol. 2021;73(7):1220-1232. doi:10.1002/art.41652.
  2. A Skewed Pool of Resident T Cells Triggers Psoriasis-Associated Tissue Responses in Never-Lesional Skin from Patients with Psoriasis. Gallais Sérézal I, Hoffer E, Ignatov B, et al. J Allergy Clin Immunol. 2019;143(4):1444-1454. doi:10.1016/j.jaci.2018.08.048.
  3. The Pathogenesis of Psoriatic Arthritis. Veale DJ, Fearon U. Lancet. 2018;391(10136):2273-2284. doi:10.1016/S0140-6736(18)30830-4.
  4. Interval Between Onset of Psoriasis and Psoriatic Arthritis Comparing the UK Clinical Practice Research Datalink with a Hospital-Based Cohort. Tillett W, Charlton R, Nightingale A, et al. Rheumatology. 2017;56(12):2109-2113. doi:10.1093/rheumatology/kex323.
  5. Prevalence of Psoriatic Arthritis in Patients with Psoriasis: A Systematic Review and Meta-Analysis of Observational and Clinical Studies. Alinaghi F, Calov M, Kristensen LE, et al. J Am Acad Dermatol. 2019;80(1):251-265. doi:10.1016/j.jaad.2018.06.027.
  6. IL-23 Induces Spondyloarthropathy by Acting on ROR-γt+ CD3+CD4−CD8− Entheseal Resident T Cells. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. Nat Med. 2012;18(7):1069-1076. doi:10.1038/nm.2817.
  7. Doxycycline-Induced Expression of Transgenic Human Tumor Necrosis Factor α in Adult Mice Results in Psoriasis-like Arthritis. Retser E, Schied T, Skryabin BV, et al. Arthritis Rheum. 2013;65(9):2290-2300. doi:10.1002/art.38026.
  8. Genome-Wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. Stuart PE, Nair RP, Tsoi LC, et al. Am J Hum Genet. 2015;97(6):816-836. doi:10.1016/j.ajhg.2015.10.019.
  9. Preventing Psoriatic Arthritis: Focusing on Patients with Psoriasis at Increased Risk of Transition. Scher JU, Ogdie A, Merola JF, Ritchlin C. Nat Rev Rheumatol. 2019;15(3):153-166. doi:10.1038/s41584-019-0175-0.
  10. Mitochondrial Variant Enrichment from High-Throughput Single-Cell RNA Sequencing Resolves Clonal Populations. Miller TE, Lareau CA, Verga JA, et al. Nat Biotechnol. 2022;40(7):1030-1034. doi:10.1038/s41587-022-01210-8.
  11. CD200+ Fibroblasts Form a Pro-Resolving Mesenchymal Network in Arthritis. Rauber S, Mohammadian H, Schmidkonz C, et al. Nat Immunol. 2024;25(4):682-692. doi:10.1038/s41590-024-01774-4.
  12. Dense Genotyping of Immune-Related Susceptibility Loci Reveals New Insights into the Genetics of Psoriatic Arthritis. Bowes J, Budu-Aggrey A, Huffmeier U, et al. Nat Commun. 2015;6:6046. doi:10.1038/ncomms7046.

Categories

Recent Posts

FDA Labeling Now Aligns with the IPC and NPF Joint Position Statement on Tuberculosis Testing

Dose Reduction of IL-17 and IL-23 Inhibitors: Are We Ready for Tailored Dosing in the Era of Disease Modification?

Remembering Dr. Craig Leonardi

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

What's New

Remembering Dr. Craig Leonardi

The International Psoriasis Council (IPC) remembers Dr. Craig Leonardi, founding member and former President, whose research shaped modern psoriasis treatment.

Read More »

Look Beyond My Skin: World Psoriasis Day 2026

World Psoriasis Day, observed each year on October 29, was launched by the International Federation of Psoriasis Associations (IFPA) in 2004 to give a voice to the more than 125 million people worldwide living with psoriasis and psoriatic arthritis. To mark this year’s observance, IPC joined the Latin American Society of Psoriasis and Dermoimmunology (SOLAPSO) and the Skin Inflammation and Psoriasis International Network (SPIN) to create a video series around the theme “Look Beyond My Skin,” featuring voices from all three organizations. Missed the videos on social media? Watch the full series on the IPC YouTube channel.

WATCH NOW

Thursday, October 29, 2026

Introducing Take Two with IPC: Expert Talks in Two Minutes

Take Two with IPC gives a longer presentation a second life in two minutes. Each video takes an expert talk IPC has already published (a Take Ten recording or a symposium presentation) and condenses the clinical substance. The series launched this month alongside the World Psoriasis Day campaign with four videos on pediatric psoriasis: Psoriasis Look-Alikes and Anti-TNF-α Induced Skin Eruptions with IPC Board Member Amy Paller, MS, MD; Conventional Therapies with IPC Councilor Mona El-Kalioby, MBBCh, MSc, MD; and Phototherapy in Pediatric Psoriasis with Fernando Valenzuela, MD. New Take Two videos will be featured each month, drawn from the Take Ten with IPC library and recordings from IPC symposia, with a link to the full presentation for each.

WATCH NOW

Thursday, October 29, 2026

Videos Now Available from the Eczema and Psoriasis Research Incubator

Select presentations from the Eczema and Psoriasis Research Incubator: Cross-Disciplinary Innovation Forum, hosted by the International Eczema Council (IEC) and International Psoriasis Council (IPC) at the 55th Annual European Society for Dermatological Research (ESDR) Meeting, are now available. Topics include disease endotypes, atopic dermatitis-psoriasis overlap, cardiovascular risk in psoriasis, and genetic susceptibility.

WATCH NOW

Monday, October 26, 2026

Sex Differences in Psoriasis

In this Take Ten with IPC video, Juul van den Reek and PhD candidate Liana Barenbrug discuss sex differences in psoriasis, why these distinctions matter, what current research tells us, and which areas should be prioritized in future psoriasis research.

WATCH NOW

Thursday, October 1, 2026